| Name | Title | Contact Details |
|---|---|---|
Darryl Vleeming |
Chief Information Officer | Profile |
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
We dont just treat cancer, we treat people. You can count on us to put you first and provide the most advanced treatments. Lets beat this together.
Oculus Innovative Sciences, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.